A Study of Baricitinib in Participants With Rheumatoid Arthritis

Inclusion Criteria:

• Participants must have at least one of the following characteristics:

• Documented evidence of a VTE prior to this study

• At least 60 years of age

• A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or

• Age 50 to less than 60 years and BMI 25 to less than 30 kg/m²

• Participants must have an inadequate response or intolerance to at least 1disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)

Exclusion Criteria:

• Participant must not have prior use of a Janus kinase (JAK) inhibitor or havereceived more than 1 prior TNF inhibitor that was:

• discontinued for IR (lack or loss of efficacy) for RA, or

• discontinued for intolerance (AE) when used for any indication

• Participants must not be pregnant or breastfeeding

• Participants must not have had more than one VTE

• Participants must not have cancer

• Participants must not have active herpes zoster, serious infection, activetuberculosis, or any other serious illness

• Participants must not have had a live vaccine within four weeks of study start

• Participants must not have participated in any other clinical trial within fourweeks of study start

• Participants must not have a history of IV drug use, other illicit drug abuse, orchronic alcohol abuse in the past year